SARS-CoV-2 cell entry and targeted antiviral development
Zinuo Chen, Ruikun Du, Jazmin Galván Achi, Lijun Rong, Qinghua Cui
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.
Topics & Concepts
PandemicCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus2019-20 coronavirus outbreakMedicineVirologyPublic healthIntensive care medicineImmunologyDiseaseInfectious disease (medical specialty)PathologyOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Outbreaks Research